Symposium: Targeting tau in AD treatment and the future for diagnostics - Symposium kindly supported by TauRx by MA Exhibitions

Dementias 2021

Host Login

Targeting tau in AD treatment and the future for diagnostics - Symposium kindly supported by TauRx

About This Webinar

This session has been kindly supported by TauRx Pharmaceticals

Professor Claude Wischik and Professor Bjoern Schelter will discuss the impact and importance of targeting tau in AD treatment and the future for diagnostics.

About TauRx Pharmaceuticals

TauRx’s mission is to discover, develop and commercialise products for the diagnosis and treatment of neurodegenerative diseases caused through protein aggregation. The early research of Professor Wischik led to the first identification of tau protein discovered by Alzheimer.

Tau pathology is widely recognised as a principal driver of clinical dementia in AD and Tau Aggregation Inhibitors (TAIs) target the formation or aggregation of tau protein ‘tangles’ in the brain. Three completed phase 3 studies of our second-generation TAI have informed the design of our fully randomised LUCIDITY study, with results expected mid-2022.

www.taurx.com

About GT Diagnostics
GT Diagnostics develops readily deployable e-platform tools for home use as well-being apps, alongside professional tools for expert use targeting the diagnosis and monitoring of dementias.

GT Diagnostics’ tools are designed to be made available through various service providers ranging from financial and professional services, personal advice and support, residential and non-residential care, to specialised dementia centres.

www.gtdiag.com

Contact Us

Claude Wischik is CEO and co-founder of TauRx: cmw@taurx.com

Glenn Corr is TauRx Chief Operating Officer: g.corr@taurx.com

Rebecca Andersen is TauRx Market Access and Communications Manager: r.andersen@taurx.com

Sonya Miller is TauRx Medical Oversight Lead: s.miller@taurx.com

Bjoern Schelter is CEO of GT Diagnostics: b.schelter@gtdiag.com

Linda Sommerlade is GT Diagnostics Head of Operations l.sommerlade@gtdiag.com

Presenters

Professor Claude Wischik

Professor of Psychiatric Geratology, University of Aberdeen

Claude Wischik is Professor of Psychiatric Geratology at University of Aberdeen and Chief Executive of TauRx Pharmaceuticals. He was born in France, grew up in Australia and studied Medicine in Adelaide, Australia.

He did his PhD at the MRC Laboratory of Molecular Biology in Cambridge and completed specialist training in Psychiatry in Cambridge. He was appointed to his current position as Professor of Old Age Psychiatry at the University of Aberdeen in 1995.

In 2002, he co-founded TauRx Pharmaceuticals as a Singapore-incorporated company with the aim of discovering novel approaches to the treatment and diagnosis of Alzheimer’s disease and related disorders based on his discovery of a short fragment of Tau as the fundamental building block of the Alzheimer neurofibrillary tangle.

He has authored 150 scientific papers in the field of AD and has over 900 granted patents and additional pending applications covering the work of the team supporting the first tau-based treatment for AD and related neurodegenerative disorders.

Professor Bjoern Schelter

Chair Professor in Applied Mathematics, University of Aberdeen

Professor Schelter is Chair Professor in Applied Mathematics at the University of Aberdeen, Scotland.

For more than 20 years, he has specialised in data-based modelling, model-based data analysis, and statistics with applications mainly in the Neurosciences.

His scientific contributions split equally into developing novel statistical analysis tools & approaches and the application thereof. Since 2012 a particular focus area of his research and work is dementia.

As CEO of GT Diagnostics he is bringing to market advanced dementia diagnostic tools in collaboration with TauRx.

This webinar will show you…

HiPAL – Memory Testing

HiPAL was designed by GT Diagnostics to monitor your cognitive status at home in a game like environment; allowing you to share your results with experts to provide a more comprehensive view.
Tau Pathological Process

Tau pathology is widely recognised as a principal driver of clinical dementia in AD and Tau Aggregation Inhibitors (TAIs) target the formation or aggregation of tau protein ‘tangles’ in the brain.
Tau Pathology in AD

The presentation will highlight the link between tau pathology and Alzheimer’s disease and the symbiotic relationship between a need for earlier AD diagnosis and targeting tau in AD treatment.